Bio-Path Holdings to Host Key Conference Call
Bio-Path Holdings, Inc. (NASDAQ: BPTH), a pioneering biotechnology company, is set to lead a significant corporate update through a live conference call and audio webcast. Scheduled for May 29, 2025, this important session aims to provide a thorough overview of the company’s innovative business strategies focused on the development of targeted cancer and obesity therapies.
How to Join the Conference Call
To participate in this informative session, attendees can dial (844) 481-3014 for domestic calls or (412) 317-1879 for international access. It is advisable to connect at least five minutes prior to the start of the presentation at 8:30 a.m. ET. Furthermore, a live audio webcast of the call will be accessible through the Presentations section of the company’s website, ensuring that stakeholders can engage with the company’s strategies and updates. An archived version of the webcast will be available roughly two hours post-event.
Innovative Technology at Bio-Path
Bio-Path Holdings is at the forefront of biotechnology, harnessing its proprietary DNAbilize antisense RNA interference (RNAi) nanoparticle technology. This groundbreaking approach enables the creation of a diverse range of nucleic acid-based therapies, tailored specifically for targeting conditions such as cancer and obesity. The company’s lead candidate, prexigebersen (BP1001), is currently undergoing a Phase 2 trial aimed at addressing blood cancers. Additionally, the modified version, BP1001-A, is advancing through a Phase 1/1b study for solid tumors and is also being assessed as a treatment for obesity among patients with Type 2 diabetes.
Pipeline of Promising Drug Candidates
Alongside BP1001, Bio-Path has developed BP1002, which targets the Bcl-2 protein and is being investigated for its efficacy against blood cancers and solid tumors like acute myeloid leukemia. Furthermore, the company is preparing to submit an Investigational New Drug (IND) application for BP1003. This novel compound consists of a liposome-incorporated antisense oligodeoxynucleotide specifically designed to inhibit STAT3, providing yet another promising avenue for cancer treatment.
Commitment to Transparency and Growth
With its sights set on advancing innovative treatments and improving patient outcomes, Bio-Path Holdings emphasizes its commitment to transparency. This conference call represents a vital opportunity for investors and interested parties to gain insight into the company's future directions and strategic initiatives that align with its mission to revolutionize cancer care and address obesity-related conditions.
Contacting Bio-Path Holdings
For those seeking to learn more about Bio-Path Holdings or have any queries related to the upcoming conference call, the company provides several contact points. Will O’Connor of Stern Investor Relations can be reached at 212-362-1200 or via email at will@sternir.com. Additionally, Doug Morris in Investor Relations at Bio-Path Holdings is available and can be contacted directly at 832-742-1369.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to provide investors and stakeholders with an in-depth overview of Bio-Path Holdings' recent innovations and future strategies.
How do I access the live conference call?
You can join the conference call by calling either (844) 481-3014 or (412) 317-1879, along with checking the company website for the audio webcast.
What stage is Bio-Path's leading drug candidate in?
Bio-Path's lead candidate, prexigebersen (BP1001), is currently in a Phase 2 clinical trial targeting blood cancers.
What other products are being developed by Bio-Path Holdings?
Bio-Path is also developing BP1002 and BP1003, targeting various cancer types and obesity-related conditions.
Who can I contact for more information about Bio-Path Holdings?
For inquiries, you can contact Will O’Connor at Stern Investor Relations or Doug Morris directly at Bio-Path Holdings.
